News

BioPharma Dive1d
Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
Fierce Biotech6h
Chutes & Ladders—Marty Makary names Vinay Prasad new CBER head
In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics ...
STAT1d
New CBER Director Vinay Prasad praises evidence, FDA reviewers in first speech to staff
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
The FDA names a new vaccine chief with an unsettling record, joining a controversial team
Dr. Vinay Prasad, the FDA's new vaccine chief, has been accused of spreading misinformation about Covid vaccines.
The American Journal of Managed Care1d
Biotech Stocks Slide After FDA Selects Prasad to Lead CBER
The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...
STAT1d
Judge deals blow to compounding pharmacies
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
Hosted on MSN2d
Sarepta price target lowered to $70 from $110 at Piper Sandler
The firm notes Tuesday has been “a doozy of a day” for Sarepta, with the announcement of Vinay Prasad as the new head of the FDA’s CBER and a miss on Q1 earnings, where Elevidys net revenue came in ...